Lifeward shareholders approve Oratech Pharma acquisition and related proposals

Lifeward Ltd.

Proposal 1 passed: issuance of ordinary shares to Oramed for Oratech acquisition (1,854,591 for, 470,084 against).
Proposal 2 passed: election of two external directors contingent on closing of Oratech acquisition.
Proposal 5 passed: equity grant to CEO Mark Grant (1,656,670 for, 674,846 against).
Proposal 6 passed: reappointment of Ernst & Young as auditor for FY 2026 (6,175,644 for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.